Replies to post #24656 on RespireRx Pharmaceuticals Inc (RSPI)

[bladerunner1717]

Neuro,

Thanks for that. By "virtual"--I should have been more explicit--I meant licensing out CX1739 and CX1942 and whatever they can get for CX717 in RD and hoping for the best, while maybe developing & running some high-impact trials in orphan indications. I do like your idea of licensing Euro rights in ADHD for CX1739, and hopefully securing enough upfront cash to run some trials here in ADHD and, hopefully, show enough positive results to obtain a lucrative U.S. partnership. But they'd have to give up the SA rights as well, I'm sure.

What's your take on what SGP is doing with COR molecules in depression and ADHD? If SGP is sitting on positive results in the just completed Phase II in ADHD, then how do you see that affecting partnership talks? How does the COR molecule in SGP's ADHD study compare with CX717?


Bladerunner